Bayer Doubles OTC Presence In China With Dihon Acquisition
This article was originally published in PharmAsia News
Bayer AG acquired its second Chinese over-the-counter company to scale up amid the country’s OTC consolidation trend.
You may also be interested in...
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?